NASDAQ:SEPN

Septerna Q2 2025 Earnings Results & Report

Septerna logo
$41.67 -0.93 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.02 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.56 versus the -$0.05 consensus estimate, while revenue of $120 thousand fell short of the $22.50 million estimate by $22.38 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Septerna EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.51
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Septerna Revenue Results

Actual Revenue
$120 thousand
Expected Revenue
$22.50 million
Beat/Miss
Missed by -$22.38 million
YoY Revenue Growth
N/A

Septerna Q2 2025 Earnings FAQ

Septerna (NASDAQ:SEPN) reported earnings of -$0.56 per share for Q2 2025, missing the consensus estimate of -$0.05. The report was announced on Monday, August 11, 2025.

Septerna reported revenue of $120 thousand for Q2 2025, against a consensus estimate of $22.50 million.

Septerna Earnings Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
Septerna (NASDAQ:SEPN) Director Sells $3,934,723.80 in Stock
Septerna FY2026 Earnings Forecast Lowered by HC Wainwright
Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development. The company has also pursued collaborations to apply its GPCR discovery capabilities to additional therapeutic programs.

View Septerna Profile